Amed S, Oram R (2016). Maturity Onset Diabetes of the youn(MODY): Making the right diagnosis to optimize treatment. Canada Journal of Diabetes 40:449-454.
Crossref

Bahnak BR, Gold AH (1982). Effects of alloxan diabetes on the turnover of rat liver glycogen synthase comparison with liver phosphorylase. Journal of Biological Chemistry 257:8775-8780.

Bailey CJ (1999). New Pharmacological approaches to glycaemic control. Diabetes Reviews 7:94-113.

Dehghan A, Kardys I, Mact D (2007). "Genetic variation of C-reactive protein levels and incidence of diabetes". Journal of Diabetes 56(3):872-878.
Crossref

Doring A, Giegei C, Mehta D (2008). "SLC2A9 influences uric acid concentration with pronounced sex-specific effects". Nature Genetics 40(4):430-436.
Crossref

Fossati P, Prencipe L, Berti G (1980). Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymatic assay of uric acid in serum and urine. Journal of Clinical Chemistry 26:227.

Lambert P, Bingley PJ (2002). What is type 1 Diabetes"? Medicine 30:1-5.
Crossref

Makkar HP, Francis G, Becker K (2007). "Bioactivity of phytochemical in some lesser-known plants and their effects and potentials application in livestock and aquaculture production system". Animal 1(9):1371-1391.
Crossref

Nakagawa T, Hu H, Zharikov S, Tuttle KR (2006). "A causal role for uric acid in fructose induced metabolic syndrome". American Journal Physiology Renal Physiology 290(3):F625-631.
Crossref

Pepys MB, Hirschfield GM (2003). C-reactive protein: a critical update. Journal of Clinical Investigation 11(12):1805-1812.
Crossref

Sacks DB, Arnold M, Bakris GL (2011). Executive summary: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Journal of Clinical Chemistry 57:793-798.
Crossref

Scoppola A, Montecci FR, Mezinger G, Lala A (2001). Urinary mevalonate excretion rate in type 2 diabetes: Role of metabolic control. Journal of Atherosclerosis 156:357-361.
Crossref

Seuring T (2015). How Much Does Type 2 Diabetes Cost? PharmacoEconomics and Outcomes News 725(1):11-14.

Sindhu S, Singh HK, Salman MT, Fatima J, Verma VK (2011). "Effects of atorvastatin and rosuvastatin or high-sensitivity C- reactive protein and lipid profile in obese type 2 diabetes mellitus patients". Journal of Pharmacology and Pharmacotherapeutics 2(4):2615.
Crossref

Szudelski T (2001). The mechanism of alloxan and streptozotocin action in beta cells of rat pancreas. Journal of Physiological Research 50(6):537-546.

Tallroth GM, Lindgren G, Sternberg I, Agadh CD (1990). Neurophysiological changes during insulin-induced hypoglycaemia and in the recovery period following glucose infusion in type 1 diabetes mellitus and normal men. Diabetologia 33:319-327.
Crossref

Tyrberg B, Anderson A (2001). "Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta cell toxin alloxan". General and Comparative Endocrinology 122(3):238-51.
Crossref

Unwin NE, Sobugwi E, Albert KGMM (2001). Type 2 diabetes: The challenge of preventing a global epidemic. Diabetes Int. pp. 11-48.

WHO Expert Committee on Diabetes Mellitus (1980). Technical Report Series 646. World Health Organization, Geneva 61 p.